Silence Therapeutics Plc - ADR Stock

$7.10

0.42% day before yesterday

Nasdaq, Dec 27, 10:05 pm CET

ISIN

US82686Q1013

Symbol

SLN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Silence Therapeutics Plc - ADR Stock price

$7.10

-12.40 63.59% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

+0.03 0.42%

ISIN

US82686Q1013

Symbol

SLN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$335.23m
Enterprise Value	$162.40m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	7.89
P/S ratio (TTM) P/S ratio	16.30
P/B ratio (TTM) P/B ratio	2.64
Revenue growth (TTM) Revenue growth	-40.10%
Revenue (TTM) Revenue	$20.57m
EBIT (operating result TTM) EBIT	$-74.19m
Free Cash Flow (TTM) Free Cash Flow	$-52.56m
Cash position	$173.02m
EPS (TTM) EPS	$-1.67
P/E forward	negative
P/S forward	12.66
EV/Sales forward	6.13
Short interest	1.19%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Silence Therapeutics Plc - ADR Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Silence Therapeutics Plc - ADR forecast:

6x Buy

100%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Silence Therapeutics Plc - ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Silence Therapeutics Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	21 21	40% 40% 100%
- Direct Costs	11 11	29% 29% 55%
Gross Profit	9.16 9.16	50% 50% 45%
- Selling and Administrative Expenses	25 25	6% 6% 122%
- Research and Development Expense	58 58	11% 11% 281%
EBITDA	-74 -74	28% 28% -358%
- Depreciation and Amortization	0.60 0.60	5% 5% 3%
EBIT (Operating Income) EBIT	-74 -74	28% 28% -361%
Net Profit	-75 -75	44% 44% -365%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Silence Therapeutics Plc - ADR Stock News

Neutral

Business Wire

●

20 days ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented ...

Neutral

Business Wire

●

about one month ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesda...

Neutral

Business Wire

●

about one month ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in athero...

More Silence Therapeutics Plc - ADR News

Company Profile

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Craig Tooman
Employees	109
Founded	1994
Website	www.silence-therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now